[{"orgOrder":0,"company":"Kylonova (Xiamen) Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Kylo-11","moa":"Lp(a)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Kylonova (Xiamen) Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kylonova (Xiamen) Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kylonova (Xiamen) Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Kylonova (Xiamen) Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Kylo-0603","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Kylonova (Xiamen) Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kylonova (Xiamen) Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kylonova (Xiamen) Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Kylonova (Xiamen) Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Kylo-12","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Kylonova (Xiamen) Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kylonova (Xiamen) Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kylonova (Xiamen) Biopharma \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Kylonova (Xiamen) Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Kylo-12 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypertriglyceridemia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 20, 2025

                          Lead Product(s) : Kylo-12

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Kylo-0603 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 15, 2024

                          Lead Product(s) : Kylo-0603

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Kylo-11 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cardiovascular Diseases.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          April 12, 2024

                          Lead Product(s) : Kylo-11

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank